202 related articles for article (PubMed ID: 37575254)
1. FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab.
Leitner J; Egerer R; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2023; 14():1208631. PubMed ID: 37575254
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab.
Ramakrishna V; Sundarapandiyan K; Zhao B; Bylesjo M; Marsh HC; Keler T
J Immunother Cancer; 2015; 3():37. PubMed ID: 26500773
[TBL] [Abstract][Full Text] [Related]
3. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.
Qi X; Li F; Wu Y; Cheng C; Han P; Wang J; Yang X
Nat Commun; 2019 May; 10(1):2141. PubMed ID: 31105267
[TBL] [Abstract][Full Text] [Related]
4. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.
Chin SM; Kimberlin CR; Roe-Zurz Z; Zhang P; Xu A; Liao-Chan S; Sen D; Nager AR; Oakdale NS; Brown C; Wang F; Yang Y; Lindquist K; Yeung YA; Salek-Ardakani S; Chaparro-Riggers J
Nat Commun; 2018 Nov; 9(1):4679. PubMed ID: 30410017
[TBL] [Abstract][Full Text] [Related]
5. M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation.
Xu C; Zhou X; Webb L; Yalavarthi S; Zheng W; Saha S; Schweickhardt R; Soloviev M; Jenkins MH; Brandstetter S; Belousova N; Alimzhanov M; Rabinovich B; Deshpande AM; Brewis N; Helming L
Cancer Immunol Res; 2024 Feb; 12(2):195-213. PubMed ID: 38091375
[TBL] [Abstract][Full Text] [Related]
6. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.
Claus C; Ferrara-Koller C; Klein C
MAbs; 2023; 15(1):2167189. PubMed ID: 36727218
[TBL] [Abstract][Full Text] [Related]
7. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity.
Cheng LS; Cheng YF; Liu WT; Shen A; Zhang D; Xu T; Yin W; Cheng M; Ma X; Wang F; Zhao Q; Zeng X; Zhang Y; Shen G
J Transl Med; 2022 Sep; 20(1):415. PubMed ID: 36076251
[TBL] [Abstract][Full Text] [Related]
8. Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.
Ho SK; Xu Z; Thakur A; Fox M; Tan SS; DiGiammarino E; Zhou L; Sho M; Cairns B; Zhao V; Xiong M; Samayoa J; Forsyth CM; Powers DB; Chao DT; Hollenbaugh D; Alvarez HM; Akamatsu Y
Mol Cancer Ther; 2020 Apr; 19(4):1040-1051. PubMed ID: 31974274
[TBL] [Abstract][Full Text] [Related]
9. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
10. CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development.
Hashimoto K
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34064598
[TBL] [Abstract][Full Text] [Related]
11. Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity.
Reitinger C; Ipsen-Escobedo A; Hornung C; Heger L; Dudziak D; Lux A; Nimmerjahn F
Front Immunol; 2022; 13():970290. PubMed ID: 36248847
[TBL] [Abstract][Full Text] [Related]
12. CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.
Wasiuk A; Testa J; Weidlick J; Sisson C; Vitale L; Widger J; Crocker A; Thomas LJ; Goldstein J; Marsh HC; Keler T; He LZ
J Immunol; 2017 Dec; 199(12):4110-4123. PubMed ID: 29109120
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
Chester C; Sanmamed MF; Wang J; Melero I
Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
[TBL] [Abstract][Full Text] [Related]
14. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
Burris HA; Infante JR; Ansell SM; Nemunaitis JJ; Weiss GR; Villalobos VM; Sikic BI; Taylor MH; Northfelt DW; Carson WE; Hawthorne TR; Davis TA; Yellin MJ; Keler T; Bullock T
J Clin Oncol; 2017 Jun; 35(18):2028-2036. PubMed ID: 28463630
[TBL] [Abstract][Full Text] [Related]
15. 4-1BB costimulation promotes bystander activation of human CD8 T cells.
Reithofer M; Rosskopf S; Leitner J; Battin C; Bohle B; Steinberger P; Jahn-Schmid B
Eur J Immunol; 2021 Mar; 51(3):721-733. PubMed ID: 33180337
[TBL] [Abstract][Full Text] [Related]
16. Costimulatory capacity of CD137 mAbs on T cells depends on elaborate CRD structures but not on blocking ligand-receptor binding.
Jin X; Yi L; Wang X; Yan Z; Wei P; Yang B; Zhang H
Eur J Immunol; 2023 Dec; 53(12):e2350493. PubMed ID: 37675596
[TBL] [Abstract][Full Text] [Related]
17. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
Saijo A; Ogino H; Butowski NA; Tedesco MR; Gibson D; Watchmaker PB; Okada K; Wang AS; Shai A; Salazar AM; Molinaro AM; Rabbitt JE; Shahin M; Perry A; Clarke JL; Taylor JW; Daras M; Oberheim Bush NA; Hervey-Jumper SL; Phillips JJ; Chang SM; Hilf N; Mayer-Mokler A; Keler T; Berger MS; Okada H
Neuro Oncol; 2024 Feb; 26(2):335-347. PubMed ID: 37758193
[TBL] [Abstract][Full Text] [Related]
18. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.
Hussain K; Hargreaves CE; Rowley TF; Sopp JM; Latham KV; Bhatta P; Sherington J; Cutler RM; Humphreys DP; Glennie MJ; Strefford JC; Cragg MS
Front Immunol; 2019; 10():390. PubMed ID: 30899264
[TBL] [Abstract][Full Text] [Related]
19. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.
Segal NH; He AR; Doi T; Levy R; Bhatia S; Pishvaian MJ; Cesari R; Chen Y; Davis CB; Huang B; Thall AD; Gopal AK
Clin Cancer Res; 2018 Apr; 24(8):1816-1823. PubMed ID: 29549159
[No Abstract] [Full Text] [Related]
20. Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice.
Wasiuk A; Weidlick J; Sisson C; Widger J; Crocker A; Vitale L; Marsh HC; Keler T; He LZ
Cancer Immunol Immunother; 2022 Jan; 71(1):97-109. PubMed ID: 34028568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
